Back to News
Market Impact: 0.35
Creative Medical Reports 93% Response Rate In Ultrasome Knee Osteoarthritis Pilot Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Creative Medical Technology Holdings said its investigational Ultrasome platform produced a 93% patient response rate and reduced average pain scores by approximately 65% in a pilot study of knee osteoarthritis. The findings are preliminary and concern an investigational platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
CELZ0.75
More News
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally